Literature DB >> 33432763

The clinical characterization of the patient with primary psychosis aimed at personalization of management.

Mario Maj1, Jim van Os2,3,4, Marc De Hert5,6, Wolfgang Gaebel7, Silvana Galderisi1, Michael F Green8,9, Sinan Guloksuz3,10, Philip D Harvey11, Peter B Jones12, Dolores Malaspina13, Patrick McGorry14,15, Jouko Miettunen16,17, Robin M Murray4, Keith H Nuechterlein18, Victor Peralta19, Graham Thornicroft20, Ruud van Winkel3,6,21, Joseph Ventura8.   

Abstract

The current management of patients with primary psychosis worldwide is often remarkably stereotyped. In almost all cases an antipsychotic medica-tion is prescribed, with second-generation antipsychotics usually preferred to first-generation ones. Cognitive behavioral therapy is rarely used in the vast majority of countries, although there is evidence to support its efficacy. Psychosocial interventions are often provided, especially in chronic cases, but those applied are frequently not validated by research. Evidence-based family interventions and supported employment programs are seldom implemented in ordinary practice. Although the notion that patients with primary psychosis are at increased risk for cardiovascular diseases and diabetes mellitus is widely shared, it is not frequent that appropriate measures be implemented to address this problem. The view that the management of the patient with primary psychosis should be personalized is endorsed by the vast majority of clinicians, but this personalization is lacking or inadequate in most clinical contexts. Although many mental health services would declare themselves "recovery-oriented", it is not common that a focus on empowerment, identity, meaning and resilience is ensured in ordinary practice. The present paper aims to address this situation. It describes systematically the salient domains that should be considered in the characterization of the individual patient with primary psychosis aimed at personalization of management. These include positive and negative symptom dimensions, other psychopathological components, onset and course, neurocognition and social cognition, neurodevelopmental indicators; social functioning, quality of life and unmet needs; clinical staging, antecedent and concomitant psychiatric conditions, physical comorbidities, family history, history of obstetric complications, early and recent environmental exposures, protective factors and resilience, and internalized stigma. For each domain, simple assessment instruments are identified that could be considered for use in clinical practice and included in standardized decision tools. A management of primary psychosis is encouraged which takes into account all the available treatment modalities whose efficacy is supported by research evidence, selects and modulates them in the individual patient on the basis of the clinical characterization, addresses the patient's needs in terms of employment, housing, self-care, social relationships and education, and offers a focus on identity, meaning and resilience.
© 2021 World Psychiatric Association.

Entities:  

Keywords:  Primary psychosis; environmental exposures; family history; internalized stigma; negative dimension; neurocognition; obstetric complications; personalization of treatment; physical comorbidities; positive dimension; practical needs; protective factors; psychiatric antecedents; psychiatric comorbidities; psychosocial interventions; recovery; resilience; schizophrenia; social cognition; social functioning

Year:  2021        PMID: 33432763      PMCID: PMC7801854          DOI: 10.1002/wps.20809

Source DB:  PubMed          Journal:  World Psychiatry        ISSN: 1723-8617            Impact factor:   49.548


  280 in total

1.  The impact of a family history of psychosis on age-at-onset and positive and negative symptoms of schizophrenia: a meta-analysis.

Authors:  Michelle L Esterberg; Hanan D Trotman; Carrie Holtzman; Michael T Compton; Elaine F Walker
Journal:  Schizophr Res       Date:  2010-03-19       Impact factor: 4.939

2.  Examining the factor structure of the recovery assessment scale.

Authors:  Patrick W Corrigan; Mark Salzer; Ruth O Ralph; Yvette Sangster; Lorraine Keck
Journal:  Schizophr Bull       Date:  2004       Impact factor: 9.306

3.  Early developmental milestones in adult schizophrenia and other psychoses. A 31-year follow-up of the Northern Finland 1966 Birth Cohort.

Authors:  M Isohanni; P B Jones; K Moilanen; P Rantakallio; J Veijola; H Oja; M Koiranen; J Jokelainen; T Croudace; M Järvelin
Journal:  Schizophr Res       Date:  2001-10-01       Impact factor: 4.939

4.  The Social Readjustment Rating Scale.

Authors:  T H Holmes; R H Rahe
Journal:  J Psychosom Res       Date:  1967-08       Impact factor: 3.006

5.  Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study.

Authors:  Keith H Nuechterlein; Joseph Ventura; Sarah C McEwen; Denise Gretchen-Doorly; Sophia Vinogradov; Kenneth L Subotnik
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

6.  Prenatal and perinatal risk and protective factors for psychosis: a systematic review and meta-analysis.

Authors:  Cathy Davies; Giulia Segre; Andrés Estradé; Joaquim Radua; Andrea De Micheli; Umberto Provenzani; Dominic Oliver; Gonzalo Salazar de Pablo; Valentina Ramella-Cravaro; Maria Besozzi; Paola Dazzan; Maddalena Miele; Gianluigi Caputo; Cecilia Spallarossa; Georgia Crossland; Athif Ilyas; Giulia Spada; Pierluigi Politi; Robin M Murray; Philip McGuire; Paolo Fusar-Poli
Journal:  Lancet Psychiatry       Date:  2020-03-24       Impact factor: 27.083

7.  Preterm Cognitive Function Into Adulthood.

Authors:  Linda D Breeman; Julia Jaekel; Nicole Baumann; Peter Bartmann; Dieter Wolke
Journal:  Pediatrics       Date:  2015-08-10       Impact factor: 7.124

8.  Efficacy of PRIME, a Mobile App Intervention Designed to Improve Motivation in Young People With Schizophrenia.

Authors:  Danielle A Schlosser; Timothy R Campellone; Brandy Truong; Kevin Etter; Silvia Vergani; Kiya Komaiko; Sophia Vinogradov
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

9.  Neurocognitive deficit in schizophrenia: a quantitative review of the evidence.

Authors:  R W Heinrichs; K K Zakzanis
Journal:  Neuropsychology       Date:  1998-07       Impact factor: 3.295

10.  Does monitoring need for care in patients diagnosed with severe mental illness impact on Psychiatric Service Use? Comparison of monitored patients with matched controls.

Authors:  Marjan Drukker; Jim van Os; Miriam Dietvorst; Sjoerd Sytema; Ger Driessen; Philippe Delespaul
Journal:  BMC Psychiatry       Date:  2011-03-21       Impact factor: 3.630

View more
  34 in total

1.  Primary psychosis: more to know, much more to do.

Authors:  William T Carpenter
Journal:  World Psychiatry       Date:  2021-02       Impact factor: 49.548

2.  The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses.

Authors:  Falk Leichsenring; Christiane Steinert; Sven Rabung; John P A Ioannidis
Journal:  World Psychiatry       Date:  2022-02       Impact factor: 49.548

3.  Psychiatric diagnosis and treatment in the 21st century: paradigm shifts versus incremental integration.

Authors:  Dan J Stein; Steven J Shoptaw; Daniel V Vigo; Crick Lund; Pim Cuijpers; Jason Bantjes; Norman Sartorius; Mario Maj
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

4.  The clinical characterization of the adult patient with bipolar disorder aimed at personalization of management.

Authors:  Roger S McIntyre; Martin Alda; Ross J Baldessarini; Michael Bauer; Michael Berk; Christoph U Correll; Andrea Fagiolini; Kostas Fountoulakis; Mark A Frye; Heinz Grunze; Lars V Kessing; David J Miklowitz; Gordon Parker; Robert M Post; Alan C Swann; Trisha Suppes; Eduard Vieta; Allan Young; Mario Maj
Journal:  World Psychiatry       Date:  2022-10       Impact factor: 79.683

5.  European Psychiatric Association guidance on assessment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Andreas Erfurth; Stefano Barlati; Federico Zanca; Giulia Maria Giordano; Louise Birkedal Glenthøj; Merete Nordentoft; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

Review 6.  European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia.

Authors:  Antonio Vita; Wolfgang Gaebel; Armida Mucci; Gabriele Sachs; Stefano Barlati; Giulia Maria Giordano; Gabriele Nibbio; Merete Nordentoft; Til Wykes; Silvana Galderisi
Journal:  Eur Psychiatry       Date:  2022-09-05       Impact factor: 7.156

7.  Multimorbidity worsened anxiety and depression symptoms during the COVID-19 pandemic in Brazil.

Authors:  Luis Fernando Silva Castro-de-Araujo; Elisângela da Silva Rodrigues; Daiane Borges Machado; Claudio Maierovitch Pessanha Henriques; Mariana Pastorello Verotti; Alessandra Queiroga Gonçalves; Talita Duarte-Salles; Richard A Kanaan; Mauricio Lima Barreto; Glyn Lewis; Jakeline Ribeiro Barbosa
Journal:  J Affect Disord       Date:  2022-07-07       Impact factor: 6.533

8.  Searching for bridges between psychopathology and real-world functioning in first-episode psychosis: A network analysis from the OPTiMiSE trial.

Authors:  Francesco Dal Santo; Eduardo Fonseca-Pedrero; María Paz García-Portilla; Leticia González-Blanco; Pilar A Sáiz; Silvana Galderisi; Giulia Maria Giordano; Julio Bobes
Journal:  Eur Psychiatry       Date:  2022-06-10       Impact factor: 7.156

9.  The lived experience of psychosis: a bottom-up review co-written by experts by experience and academics.

Authors:  Paolo Fusar-Poli; Andrés Estradé; Giovanni Stanghellini; Jemma Venables; Juliana Onwumere; Guilherme Messas; Lorenzo Gilardi; Barnaby Nelson; Vikram Patel; Ilaria Bonoldi; Massimiliano Aragona; Ana Cabrera; Joseba Rico; Arif Hoque; Jummy Otaiku; Nicholas Hunter; Melissa G Tamelini; Luca F Maschião; Mariana Cardoso Puchivailo; Valter L Piedade; Péter Kéri; Lily Kpodo; Charlene Sunkel; Jianan Bao; David Shiers; Elizabeth Kuipers; Celso Arango; Mario Maj
Journal:  World Psychiatry       Date:  2022-06       Impact factor: 79.683

10.  What is Missing in Treatment Guidelines?

Authors:  William T Carpenter
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.